Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy
Year: 2025
Type: article
Language: en
Topic: Advanced Breast Cancer Therapies
Authors and affiliations:
raw_author_name: Urszula Pakulska
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Marta Obacz
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Jerzy Woźnicki
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Katarzyna Wiklik
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Samarpana Chakraborty
raw_affiliation_strings: Department of Molecular Oncology, Albert Einstein College of Medicine, New York, USA
raw_author_name: Marta Micek
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Vakul Mohanty
raw_affiliation_strings: Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA
raw_author_name: Diego Coelho
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Elżbieta Adamczyk
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Aniela Gołas
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Adrianna Moszyńska
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Hui Zhang
raw_affiliation_strings: Department of Molecular Oncology, Albert Einstein College of Medicine, New York, USA
raw_author_name: Magdalena Cybulska-Lubak
raw_affiliation_strings: Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
raw_author_name: Ewelina Kaniuga
raw_affiliation_strings: Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
raw_author_name: Zuzanna Sandowska-Markiewicz
raw_affiliation_strings: Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
raw_author_name: Marina Konopleva
raw_affiliation_strings: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
Department of Molecular Pharmacology, Albert Einstein College of Medicine, New York, USA
raw_author_name: Michał Mikula
raw_affiliation_strings: Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
raw_author_name: Przemysław Juszczyński
raw_affiliation_strings: Institute of Hematology and Transfusion Medicine, Warsaw, Poland
raw_author_name: Aditi Shastri
raw_affiliation_strings: Department of Molecular Oncology, Albert Einstein College of Medicine, New York, USA
raw_author_name: Natalia Baran
raw_affiliation_strings: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
Institute of Hematology and Transfusion Medicine, Warsaw, Poland
University Hospital Bern, University Hospital of Hematology and Hematological Central Laboratory Inselspital, Bern, Switzerland
raw_author_name: Tomasz Rzymski
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland
raw_author_name: Milena Mazan
raw_affiliation_strings: Ryvu Therapeutics, Krakow, Poland